European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib
Barbara Gamberi(University of Modena and Reggio Emilia), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Barbara Rosettani(National and Kapodistrian University of Athens), Meletios Α. Dimopoulos(Korea University), Gerard Crotty, Monique C. Minnema(University Medical Center Utrecht), Anders Waage(St Olav's University Hospital), Björn Andréasson(NU Hospital Group), Elena Zamagni(Istituti di Ricovero e Cura a Carattere Scientifico), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), Eleni Tholouli(Manchester Royal Infirmary), Roman Hájek(University Hospital Ostrava), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Niels Frost Andersen(Aarhus University Hospital), Christian Berthou(Centre Hospitalier Régional Universitaire de Brest), Jo Caers(University of Liège), Pamela Bacon(National and Kapodistrian University of Athens), Antonia Di Micco(National and Kapodistrian University of Athens)
Cited by 1
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k